Plasmacytoid urothelial carcinoma is rare and aggressive, with poor outcomes and challenges in accurate staging. National and institutional data reveal discrepancies in chemotherapy use and disease ...

APPs can significantly alleviate workforce shortages in urology by handling routine clinical tasks, allowing urologists to focus on complex cases. Successful integration of APPs requires changing ...

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life ...

A panelist discusses how significant unmet needs in NMIBC treatment persist around BCG supply shortages, optimal treatment sequencing, biomarker development for patient selection, and reducing ...

ImmunityBio aims to expand Anktiva's approval for BCG-unresponsive NMIBC with papillary tumors, potentially reducing radical cystectomy rates. The QUILT-3.032 trial demonstrated promising disease-free ...

"We are trying to develop epigenetic biomarkers that can predict patients that are starting to progress to neuroendocrine prostate cancer," says Jindan Yu, MD, PhD. In this video, Jindan Yu, MD, PhD, ...

Urology in the Lab: Researchers link EBV to multiple sclerosis ...

“The patients I find that have the most pronounced benefit are the patients with the very large prostates, or the patients who are catheter dependent with concern for neurogenic or myogenic bladder ...

Illuccix is approved in Europe for PSMA-positive lesion detection in prostate cancer, following prior approvals in the US, Australia, and Canada. The phase 3 VISION trial showed 177Lu-PSMA-617 plus ...

CMS has selected 15 additional drugs for Medicare Part D price negotiations, aiming to lower healthcare costs for enrollees. The Inflation Reduction Act allows Medicare to negotiate drug prices, with ...

"My biggest hope for people reading this review is to understand that there are some golden opportunities for research," says Laura Bukavina, MD, MPH, MSc. Isali: I think our review mainly highlighted ...

Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings ...